Sanofi (SNY) Key Metrics
SNY key metrics, 2016–2025
Fiscal year ended December 31, 2025 · eurosSNY returns How much profit the business earns on the capital it uses.
SNY financial health Debt, liquidity and how easily interest is covered.
SNY efficiency & capital use Working capital cycle and where the cash goes.
SNY returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SNY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SNY cash returned to shareholders
SNY key metrics in euros
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 10.5% | 7.3% | 7.3% | 11.7% | 9.4% | 20.1% | 4.7% | 7.4% | 14.6% | 8.1% |
| Return on invested capital (ROIC) | 9.3% | 6.9% | 6.9% | 10.0% | 8.5% | 16.6% | 3.9% | 6.0% | 6.2% | 7.7% |
| Return on assets (ROA) | 6.0% | 4.3% | 4.3% | 6.8% | 5.3% | 10.8% | 2.5% | 4.1% | 8.2% | 4.5% |
| Return on tangible assets | 13.2% | 8.3% | 10.2% | 15.2% | 12.3% | 23.8% | 5.3% | 9.5% | 18.1% | 8.8% |
| Free cash flow margin | 21.7% | 13.3% | 17.7% | 20.5% | 21.6% | 14.3% | 15.8% | 10.0% | 15.0% | 16.6% |
| Income quality (OCF / net income) | 1.55 | 1.63 | 1.90 | 1.26 | 1.69 | 0.60 | 2.80 | 1.29 | 0.88 | 1.66 |
| Financial health | ||||||||||
| Total debt | €20.33B | €17.91B | €18.70B | €21.21B | €22.41B | €23.68B | €25.98B | €24.70B | €15.60B | €18.58B |
| Cash & short-term investments | €8.47B | €7.93B | €8.71B | €12.74B | €10.10B | €13.91B | €9.85B | €7.12B | €10.31B | €10.38B |
| Net debt | €11.86B | €9.98B | €9.99B | €8.48B | €12.32B | €9.76B | €16.13B | €17.58B | €5.29B | €8.20B |
| Debt / equity | 0.28 | 0.23 | 0.25 | 0.28 | 0.33 | 0.38 | 0.44 | 0.42 | 0.27 | 0.32 |
| Debt / assets | 0.16 | 0.13 | 0.15 | 0.17 | 0.19 | 0.21 | 0.23 | 0.22 | 0.16 | 0.18 |
| Net debt / EBITDA | 0.95 | 0.90 | 0.88 | 0.63 | 1.07 | 0.56 | 1.51 | 1.92 | 0.55 | 0.83 |
| Current ratio | 1.09 | 1.46 | 1.27 | 1.42 | 1.44 | 1.75 | 1.42 | 1.42 | 1.70 | 1.62 |
| Quick ratio | 0.73 | 1.14 | 0.87 | 1.05 | 1.03 | 1.32 | 1.03 | 0.99 | 1.26 | 1.20 |
| Interest coverage | 15.3 | 11.6 | 13.6 | 26.4 | 21.5 | 32.8 | 5.7 | 9.6 | 17.4 | 16.3 |
| Working capital | €2.61B | €13.43B | €6.46B | €10.06B | €9.27B | €14.46B | €8.55B | €7.27B | €10.89B | €10.25B |
| Invested capital | €83.24B | €87.49B | €84.03B | €83.26B | €81.00B | €72.87B | €75.36B | €76.61B | €63.36B | €65.75B |
| Tangible asset value | €4.15B | €11.84B | €630.0M | €3.62B | −€432.0M | €547.0M | −€1.80B | −€7.09B | €4.89B | €6.56B |
| Net current asset value | −€24.14B | −€12.35B | −€21.46B | −€17.54B | −€20.65B | −€17.46B | −€24.46B | −€27.73B | −€15.22B | −€20.26B |
| Capital allocation | ||||||||||
| Dividends paid | €5.39B | €4.70B | €4.45B | €4.17B | €4.01B | €3.94B | €3.83B | €3.77B | €3.71B | €3.76B |
| Share buybacks (net) | €5.68B | €302.0M | €593.0M | €497.0M | €382.0M | €822.0M | €9.0M | €1.10B | €2.16B | €2.91B |
| Dividend payout ratio | 68.9% | 84.6% | 82.5% | 49.8% | 64.4% | 32.0% | 139.2% | 87.6% | 44.1% | 79.8% |
| Dividends + buybacks / free cash flow | 109.1% | 85.0% | 68.6% | 56.0% | 51.8% | 89.2% | 64.8% | 136.5% | 108.3% | 115.8% |
| Capex / revenue | 4.3% | 7.2% | 7.0% | 5.4% | 5.2% | 5.6% | 4.7% | 5.5% | 5.4% | 6.0% |
| Capex / operating cash flow | 16.4% | 35.2% | 28.3% | 20.9% | 19.4% | 28.1% | 23.2% | 35.6% | 26.5% | 26.6% |
| Capex / depreciation | 0.35 | 0.89 | 0.66 | 0.64 | 0.61 | 0.57 | 0.24 | 0.46 | 0.53 | 0.63 |
| Stock-based compensation / revenue | — | — | 0.7% | −0.6% | −0.3% | −19.7% | −0.3% | 0.8% | 0.7% | 0.7% |
| R&D / revenue | 16.8% | 16.7% | 15.6% | 16.0% | 14.5% | 14.8% | 16.0% | 16.5% | 15.1% | 14.9% |
| SG&A / revenue | 21.9% | 20.7% | 25.7% | 25.9% | 24.4% | 0.0% | 26.3% | 27.8% | 28.1% | 27.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 84.7 | 89.3 | 95.5 | 92.4 | 92.0 | 97.9 | 94.2 | 92.2 | 89.3 | 94.2 |
| Days of inventory on hand | 274.7 | 263.9 | 269.2 | 271.5 | 254.2 | 245.3 | 235.7 | 228.1 | 215.5 | 228.7 |
| Days payables outstanding | 208.6 | 205.6 | 204.4 | 199.6 | 170.9 | 159.2 | 157.7 | 154.4 | 140.3 | 138.4 |
| Cash conversion cycle (days) | 150.9 | 147.6 | 160.4 | 164.3 | 175.2 | 184.0 | 172.2 | 165.9 | 164.4 | 184.5 |
| Receivables turnover | 4.31 | 4.09 | 3.82 | 3.95 | 3.97 | 3.73 | 3.87 | 3.96 | 4.09 | 3.88 |
| Payables turnover | 1.75 | 1.77 | 1.79 | 1.83 | 2.14 | 2.29 | 2.31 | 2.36 | 2.60 | 2.64 |
| Inventory turnover | 1.33 | 1.38 | 1.36 | 1.34 | 1.44 | 1.49 | 1.55 | 1.60 | 1.69 | 1.60 |
| Asset turnover | 0.36 | 0.34 | 0.33 | 0.33 | 0.33 | 0.33 | 0.34 | 0.34 | 0.35 | 0.34 |
| Average receivables | €10.84B | €10.83B | €10.89B | €10.27B | €9.87B | €10.02B | €9.71B | €9.01B | €8.86B | €8.95B |
| Average payables | €7.46B | €7.44B | €7.07B | €6.50B | €5.74B | €5.30B | €5.18B | €4.84B | €4.46B | €4.06B |
| Average inventory | €9.82B | €9.55B | €9.31B | €8.84B | €8.53B | €8.17B | €7.74B | €7.15B | €6.86B | €6.70B |
| Intangibles / total assets | 53.3% | 49.7% | 58.3% | 56.4% | 57.8% | 54.8% | 54.2% | 59.4% | 53.4% | 48.9% |
Computed from SNY's annual financial statements (latest annual report filed February 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
SNY valuation and financial ratios
Sanofi earned a return on equity of 10.5% and a return on invested capital of 9.3% in fiscal 2025. It ended the year with €20.3 billion of debt and €8.5 billion in cash and short-term investments, net debt of €11.9 billion. It returned €11.1 billion to shareholders: €5.4 billion in dividends and €5.7 billion in share buybacks, 109% of free cash flow.
See the SNY income statement, the SNY chart for price history, or the SNY stock overview for the latest quote and news.
SNY key metrics FAQ
What is Sanofi's return on equity?
Sanofi's return on equity (ROE) was 10.5% in fiscal 2025: net income of €7.8 billion on average shareholders' equity of €74.4 billion.
What is Sanofi's ROIC?
Sanofi's return on invested capital was 9.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Sanofi have?
Sanofi had total debt of €20.3 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.28 and €11.9 billion of net debt (0.95 times EBITDA).
Does Sanofi buy back its shares?
Yes. Sanofi spent €5.7 billion on net share repurchases in fiscal 2025.
What is Sanofi's current ratio?
Sanofi's current ratio was 1.09 at the end of fiscal 2025: current assets were 1.09 times current liabilities.